A dose-response evaluation of inactivated influenza vaccine given intranasally and intramuscularly to healthy young adults

Vaccine

Volumn 25, Issue 29, 2007, Pages 5367-5373

  Atmar, Robert L ^a   Keitel, Wendy A ^a   Cate, Thomas R ^a   Munoz, Flor M ^a   Ruben, Fred ^b   Couch, Robert B ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b SANOFI PASTEUR   (France)

Author keywords

Immunogenicity; Inactivated vaccine; Influenza; Intramuscular; Intranasal; Safety

Indexed keywords

HEMAGGLUTINATION INHIBITING ANTIBODY; IMMUNOGLOBULIN A; INACTIVATED VACCINE; INFLUENZA VACCINE; PLACEBO; TRIPLE VACCINE;

ADULT; ANTIBODY RESPONSE; ANTIBODY TITER; ARM TENDERNESS; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG INDICATION; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FEVER; HEADACHE; HEMAGGLUTINATION INHIBITION; HUMAN; HUMAN EXPERIMENT; IMMUNOGENICITY; INFLUENZA; INJECTION SITE ERYTHEMA; INJECTION SITE REACTION; INJECTION SITE SWELLING; MALAISE; MALE; NORMAL HUMAN; NOSE IRRITATION; NOSE OBSTRUCTION; PAIN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHINORRHEA; TASTE DISORDER; THROAT IRRITATION; UNITED STATES;

ADMINISTRATION, INTRANASAL; ADOLESCENT; ADULT; ANTIBODIES, VIRAL; DOSE-RESPONSE RELATIONSHIP, IMMUNOLOGIC; DOUBLE-BLIND METHOD; FEMALE; HEMAGGLUTINATION INHIBITION TESTS; HUMANS; IMMUNOGLOBULIN A; INFLUENZA VACCINES; INJECTIONS, INTRAMUSCULAR; MALE; MIDDLE AGED; NASAL MUCOSA; PLACEBOS; VIRAL VACCINES;

EID: 34250800842     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2007.05.002     Document Type: Article

References (25)

1. Smith N.M., Bresee J.S., Shay D.K., Uyeki T.M., Cox N.J., and Strikas R.A. Prevention and control of influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 55 (2006) 1-42
2. Barker W.H., and Mullooly J.P. Influenza vaccination of elderly persons. Reduction in pneumonia and influenza hospitalizations and deaths. JAMA 244 (1980) 2547-2549
3. Keitel W.A., Atmar R.L., Cate T.R., Petersen N.J., Greenberg S.B., Ruben F., et al. Safety of high doses of influenza vaccine and effect on antibody responses in elderly persons. Arch Intern Med 166 (2006) 1121-1127
4. Keitel W.A., and Couch R.B. Inactivated influenza vaccines. In: Potter C.W. (Ed). Influenza (2002), Elsevier, New York 145-177
5. Gross P.A., Quinnan Jr. G.V., Weksler M.E., Gaerlan P.F., and Denning C.R. Immunization of elderly people with high doses of influenza vaccine. J Am Geriatr Soc 36 (1988) 209-212
6. Keitel W.A., Couch R.B., Cate T.R., Hess K.R., Baxter B., Quarles J.M., et al. High doses of purified influenza A virus hemagglutinin significantly augment serum and nasal secretion antibody responses in healthy young adults. J Clin Microbiol 32 (1994) 2468-2473
7. Keitel W.A., Cate T.R., Atmar R.L., Turner C.S., Nino D., Dukes C.M., et al. Increasing doses of purified influenza virus hemagglutinin and subvirion vaccines enhance antibody responses in the elderly. Clin Diagn Lab Immunol 3 (1996) 507-510
8. Palache A.M., Beyer W.E., Sprenger M.J., Masurel N., de Jonge S., Vardy A., et al. Antibody response after influenza immunization with various vaccine doses: a double-blind, placebo-controlled, multi-centre, dose-response study in elderly nursing-home residents and young volunteers. Vaccine 11 (1993) 3-9
9. Remarque E.J., van Beek W.C., Ligthart G.J., Borst R.J., Nagelkerken L., Palache A.M., et al. Improvement of the immunoglobulin subclass response to influenza vaccine in elderly nursing-home residents by the use of high-dose vaccines. Vaccine 11 (1993) 649-654
10. Ruben F.L., Potter C.W., and Stuart-Harris C.H. Humoral and secretory antibody responses to immunization with low and high dosage split influenza virus vaccine. Arch Virol 47 (1975) 157-166
11. Kasel J.A., Hume E.B., Fulk R.V., Togo Y., Huber M., and Hornick R.B. Antibody responses in nasal secretions and serum of elderly persons following local or parenteral administration of inactivated influenza virus vaccine. J Immunol 102 (1969) 555-562
12. Kasel J.A., Rossen R.D., Fulk R.V., Fedson D.S., Couch R.B., and Brown P. Human influenza: aspects of the immune response to vaccination. Ann Intern Med 71 (1969) 369-398
13. Waldman R.H., Kasel J.A., Fulk R.V., Togo Y., Hornick R.B., Heiner G.G., et al. Influenza antibody in human respiratory secretions after subcutaneous or respiratory immunization with inactivated virus. Nature 218 (1968) 594-595
14. Muszkat M., Greenbaum E., Ben Yehuda A., Oster M., Yeu'l E., Heimann S., et al. Local and systemic immune response in nursing-home elderly following intranasal or intramuscular immunization with inactivated influenza vaccine. Vaccine 21 (2003) 1180-1186
15. Keitel W.A., Cate T.R., Nino D., Huggins L.L., Six H.R., Quarles J.M., et al. Immunization against influenza: comparison of various topical and parenteral regimens containing inactivated and/or live attenuated vaccines in healthy adults. J Infect Dis 183 (2001) 329-332
16. Fulk R.V., Fedson D.S., Huber M.A., Fitzpatrick J.R., Howar B.F., and Kasel J.A. Antibody responses in children and elderly persons following local or parenteral administration of an inactivated influenza virus vaccine, A2-Hong Kong-68 variant. J Immunol 102 (1969) 1102-1105
17. Frank A.L., Puck J., Hughes B.J., and Cate T.R. Microneutralization test for influenza A and B and parainfluenza 1 and 2 viruses that uses continuous cell lines and fresh serum enhancement. J Clin Microbiol 12 (1980) 426-432
18. Greenbaum E., Furst A., Kiderman A., Stewart B., Levy R., Schlesinger M., et al. Mucosal [SIgA] and serum [IgG] immunologic responses in the community after a single intra-nasal immunization with a new inactivated trivalent influenza vaccine. Vaccine 20 (2002) 1232-1239
19. Greenbaum E., Engelhard D., Levy R., Schlezinger M., Morag A., and Zakay-Rones Z. Mucosal (SIgA) and serum (IgG) immunologic responses in young adults following intranasal administration of one or two doses of inactivated, trivalent anti-influenza vaccine. Vaccine 22 (2004) 2566-2577
20. Treanor J., Nolan C., O'Brien D., Burt D., Lowell G., Linden J., et al. Intranasal administration of a proteosome-influenza vaccine is well-tolerated and induces serum and nasal secretion influenza antibodies in healthy human subjects. Vaccine 24 (2006) 254-262
21. Langley J.M., Halperin S.A., McNeil S., Smith B., Jones T., Burt D., et al. Safety and immunogenicity of a Proteosome-trivalent inactivated influenza vaccine, given nasally to healthy adults. Vaccine 24 (2006) 1601-1608
22. Boyce T.G., Hsu H.H., Sannella E.C., Coleman-Dockery S.D., Baylis E., Zhu Y., et al. Safety and immunogenicity of adjuvanted and unadjuvanted subunit influenza vaccines administered intranasally to healthy adults. Vaccine 19 (2000) 217-226
23. Clements M.L., Betts R.F., Tierney E.L., and Murphy B.R. Serum and nasal wash antibodies associated with resistance to experimental challenge with influenza A wild-type virus. J Clin Microbiol 24 (1986) 157-160
24. Belshe R.B., Gruber W.C., Mendelman P.M., Mehta H.B., Mahmood K., Reisinger K., et al. Correlates of immune protection induced by live, attenuated, cold-adapted, trivalent, intranasal influenza virus vaccine. J Infect Dis 181 (2000) 1133-1137
25. Couch R.B., Kasel J.A., Six H.R., Cate T.R., and Zahradnik J.M. Immunological reactions and resistance to infection with influenza virus. In: Stuart-Harris C., and Potter C.W. (Eds). The molecular virology and epidemiology of influenza (1984), Academic Press, New York 119-144